Introduction
Hemophilia B, an X-linked severe bleeding disorder caused by the deficiency of blood clotting factor IX (FIX), is one of the most extensively studied disease models for gene therapy. Long-term correction of the bleeding disorder has been achieved in the murine and dog models of hemophilia B using adeno-associated viral (AAV) vectors. 1 Two clinical trials have also been carried out using vectors based on AAV serotype 2.
2
Muscle and liver are the two main targets for AAV-mediated gene therapy for hemophilia B. Liver-targeted delivery seems attractive for administration of AAV2-FIX vectors, because of the higher levels of FIX achieved due to more efficient gene transfer and reduced immune response to the transgene. 3, 4 Several groups have shown that hepatic delivery of AAV2-FIX vectors results in long-term high levels of FIX in normal and hemophilic mice, and therapeutic levels in hemophilia B dogs and primate models. [5] [6] [7] [8] [9] [10] Inhibitor formation against FIX by this route of administration in mice is very rare, although it could happen in some strains of mice and it correlated with low FIX expression. 11 Among the hemophilia B dogs treated with AAV vectors via the liver approach, only one dog with the null mutation developed anti-cFIX antibodies that resulted in transient FIX expression. 9 A phase I/II clinical trial for liver-directed AAV2-mediated gene transfer for severe hemophilia B has showed vectors were well tolerated.
12
Patients treated with low vector doses showed no vector-related toxicity but also failed to achieve FIX levels above baseline. Transient FIX expression at the range of 5-12% was detected in a patient who received 5x10 12 vg/kg but after a transient elevation of liver transaminases, FIX levels decreased to <1%. A second patient at the same cohort with higher pre-existing neutralizing antibody (NAB) titer against AAV2 (1:17) only had a
For personal use only. on October 23, 2017 . by guest www.bloodjournal.org From transient FIX expression at 1-3% for 2 weeks. These data suggest that: 1) the high prevalence of pre-existing immunity to AAV2 in the human population could interfere with AAV transduction and would preclude efficient in vivo gene delivery in clinical trials; 2) in vivo transduction efficiency of AAV2 is still relatively low. At low dose, there is no toxicity, but also no gene transfer. At high dose, there is gene transfer, however, hepatotoxicity was observed. Thus, an improved vector with higher efficiency and less pre-existing immunity in human would be highly desirable.
Alternative serotypes of AAV could circumvent these drawbacks. We have recently identified an expanding family of AAVs from human and nonhuman primate tissues of which at least 3 are serologically different from serotypes 1-6; these are called AAV7, 8, 9. 13 Pseudotyping strategies have been developed to cross package vector with AAV2 ITRs with capsids from other serotypes. 14 Increased in vivo gene transfer efficiency with vectors of other AAV serotypes have been reported. [14] [15] [16] [17] [18] [19] Our initial evaluation of these vectors has showed that AAV8 is especially efficient in transduction of mouse liver cells (1-2 logs more efficient than other AAV serotypes).
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Preimmunization with other AAV serotypes in C57BL/6 mice did not block further transduction by AAV2/8 vectors. Neutralizing antibody screen against AAV8 only detected low titer (1:20) in 3 out of 52 normal human subjects, whereas substantially higher titer were observed in up to 20% of human subjects for AAV2. 19 Thus, AAV8 appear to be an attractive candidate for liver-directed hemophilia gene therapy. 
Materials and methods

Vector construction, production, purification, and titration
The AAV vector plasmid pAAV-LSP-cFIX-WPRE was described previously. 8 All AAV vectors used in this study were made by the Vector Core of the University of Pennsylvania. AAV vectors were produced by three plasmids cotransfection methods as described by Xiao et al. 21 with modifications. A pseudotyping strategy was used to produce AAV vectors packaged with AAV5 and AAV8 capsid proteins by using AAV trans plasmid containing AAV2 rep and capsid from AAV5 (packH) or AAV8 (p5E18-VD2/8). 17, 19 Fifty 15-cm plates of semi-confluent 293 cells were cotransfected with 650µg of AAV vector plasmid, 650µg of AAV trans plasmid, and 1300µg of Ad helper plasmid pAd F6 by standard calcium phosphate method. Cells were harvested 3 days after transfection. AAV vectors used in this study were purified by three rounds of cesium chloride gradient centrifugation, and buffer-exchanged with PBS and concentrated using Amicon Ultra 15 centrifugal filter devices-100K (Millipore, Bedford, MA).
All AAV vectors were subjected to three routine quality control assays including genome titration by Real-time PCR using primer/probe set corresponding to the polyA region of the vector and linearized plasmid standard, infectious center assay (ICA) 22 on B50 cells 23 , and endotoxin assay using QCL-1000 ® Chromogenic LAL Test Kit (Cambrex Bio Science, Walkersville, MD). The whole blood clotting time (WBCT) and the activated partial thromboplastin time (aPTT) were performed as previously described. 24 Canine FIX antigen levels in dog plasma were determined by ELISA as described with modifications. 25 27 . Both treated and untreated samples were assayed at the same time for cFIX levels by ELISA.
Intraportal administration of rAAV vectors.
Canine liver enzymes
Canine blood chemistries (GGT, AST, ALT, alkaline phosphatase, and total bilirubin)
were analyzed in an automated clinical laboratory. reported in the literature on AAV serotype 2-treated hemophilia B dogs. At day 4, cFIX levels in G43 peaked at 1.25 µg/ml and maintained through day 9, then it gradually decreased to 466 ng/ml at day 17, followed by a gradual increase to 1.58 µg/ml at day 77 and stabilized around 1.3+0.2 µg/ml through the duration of the experiment (15.7 months). This level is about 26% of normal level of cFIX, 5-fold of the therapeutic levels of FIX (Fig. 1C) . In H12, a higher peak of cFIX expression at 3.8 µg/ml was achieved at day 5, then it gradually decreased to 210 ng/ml at day 21, the cFIX expression levels then slowly increased to 458 ng/ml at day 64 and subsequently maintained at 468+110 ng/ml for 14.3 months. This level is almost twice the therapeutic level of FIX for hemophilia B.
AAV neutralizing antibody assays
In addition, no spontaneous bleeding episodes have occurred in either dog for over one year since the treatment with AAV2/8 vectors. The hemophilia B dogs from the UNC Chapel Hill colony have on average six bleeds per year that require treatment with normal canine plasma. 24 As one of the gamma-carboxylated plasma proteins, plasma factor IX can efficiently bind to barium sulfate through the multiple gamma-carboxylated glutamic acid residues localized in the amino-terminal region. This unique property has been used for purification of various gamma-carboxylated proteins or to eliminate the interference in activity by endogenous animal factor IX in the serum added to the culture media in tissue culture experiments. 27 To test if the expressed cFIX was fully carboxylated, barium sulfate precipitation was performed on plasma samples from two time points for each dog. In the day 144 and day 529 samples of G43, 43.7% and 25.2%, respectively, were retained in the supernatant after barium sulfate treatment. And in the day 148 and day 485 samples of H12, 42.3% and 58.6%, respectively, were retained in the supernatant. In the same assay, 37.7% of cFIX was retained in the normal dog plasma (Sigma) after barium sulfate treatment. Thus, except the d529 sample of G43, cFIX in the AAV2/8-treated dogs were less than fully gamma carboxylated.
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AAV2/8 and 2/5 vectors in AAV2 pretreated hemophilia B dogs
The ability to reinject AAV to hemophilia B dog liver was studied with a dog that received AAV2/8-cFIX 2.7 years after the initial administration of AAV2-cFIX-W. D39, a female hemophilia B dog that was previously treated with 2.8x10
12 GC/kg of AAV2 LSP-cFIX-W via intraportal injection at the age of 2.8 month, has sustained expression of low levels of cFIX at 34.2+9.8 ng/ml since vector injection. 8 Although both WBCT and aPTT values were shortened after the first treatment, a total of six spontaneous bleeding episodes that require plasma infusion have occurred during the 2.7 years since the first AAV2 vector treatment. At day 995 after the first injection, D39 received a second intraportal injection with total 1.5x10 14 GC of AAV2/8 LSP-cFIX-W vector (vector dose = 9.28x10 12 GC/kg). WBCT decreased quickly from 19 min before injection to 8 min at day 6, then increased to 14.5 min at day 14 and remained stable at an average of 12.7+1.6 min for over two years since the second injection ( Fig. 2A) . aPTT was corrected to normal levels transiently, from 57.2 sec before injection to 28.9 sec at day 6, and gradually increased and stabilized at an average of 48.6+5.1 sec for over two years after the readministration (Fig. 2B) . The reduction of aPTT value post readministration of AAV2/8 vector was significant (p < 0.001, ANOVA). The pattern of cFIX expression correlated well with FIX functional assays. cFIX antigen rose quickly to 9.5 µg/ml at day 3, and 10.4 µg/ml at day 6, twice the normal level of cFIX in dogs. The cFIX level decreased after day 6 to 1.4 µg/ml at day 14 and stabilized at an average of 785 ng/ml (16% of normal level) for over two years (Fig. 2C ). and half years since the second injection (Fig. 2D) . aPTT was corrected to normal levels transiently, from 66.5 sec before injection to 29.3-32 between day 7 and day 10, then gradually increased and sustained at an average of 47.6+6.3 sec for two and half years after the readministration (Fig. 2E) . The reduction of aPTT value post readministration of AAV2/5 vector was significant (p < 0.001, ANOVA). An early peak of cFIX antigen level was reached at day 7 (4.6 µg/ml), close to the normal level of cFIX in dogs. The cFIX level decreased after day 7 to 1.7 µg/ml at day 13 and stabilized at an average of 799 ng/ml (16% of normal level) for two and half years (Fig.2C ).
Barium sulfate precipitation was also performed on plasma samples from two time points for each dog to test if the expressed cFIX was fully carboxylated. In the day 156 and day 849 samples of D39 following AAV2/8 vector administration, 58.3% and 51.3%, respectively, were retained in the supernatant after barium sulfate treatment. And
in the day 139 and day 944 samples of C52, 54.5% and 54.8%, respectively, were retained in the supernatant. In the same assay, 37.7% of cFIX was retained in the normal dog plasma (Sigma) after barium sulfate treatment. These results suggested that cFIX in the AAV2/8 and AAV2/5-treated dogs were less than fully gamma carboxylated.
Lack of vector-related toxicity or antibody response against cFIX
Serum chemistry panels including liver enzyme levels were closely monitored following vector infusion. In G43 and H12, the two naïve hemophilia B dogs injected with
5.25x10
12 GC/kg of AAV2/8 vectors, alanine aminotransferase (ALT), aspartate aminotransferase (AST) and total bilirubin remained within the normal range for over a year after vector infusion ( Fig. 3A and 3B , and data not shown). D39 had elevated AST (2.5 times upper level of normal) at day 2 and day 3 following infusion with 9.28x10 12 GC/kg of AAV2/8 vector, and its ALT was slightly over the normal range at day 3 (121 U/L) ( Fig. 3C and 3D ). C52 had elevated ALT (within 1.5 times upper level of normal) during the first 2 to 4 day after readministration with 2.3x10 13 GC/kg of AAV2/5 vector, and its AST was slightly over the normal range at day 2 (88 U/L) ( Fig. 3E and 3F) 
Humoral response to AAV following vector administration in dogs
The two naïve hemophilia B dogs that received 5.25x10 12 GC/kg of AAV2/8 vector intraportally had robust humoral response to AAV8 capsid (Fig. 4A) . In G43, NAB to AAV8 quickly rose from <1:20 preinjection to a titer of 1:320 at day 4 and peaked on day 8 at a high titer of 1:5120. The peak then gradually dropped 2-to 8-fold after week 6 and persisted through the experiment (1 year). The peak level of AAV8-NAB response in H12 was 4-8 fold less than it was in G43.
D39 developed a peak NAB response to AAV2 on day 4 after the initial administration with 2.8x10 12 GC/kg of AAV2-cFIX, the titer decreased about 1-log within a month and maintained at that level for the first year, then the titer further decreased 2-to 4-fold and persisted through the second year. By the time of the second injection (day 994), the NAB titer to AAV2 was <1:20 (Fig. 4B) . After the readministration with AAV2/8-cFIX, AAV8-NAB titer quickly rose from <1:20 preinjection to 1:1280 on day 6 and peaked at 1:5120 on day 14. The titer gradually dropped about 1-log during the two years following vector readministration.
Surprisingly, concurrent with the AAV8-NAB response, D39 displayed a similar pattern of AAV2-NAB response after the readministration of AAV2/8 vector. The peak levels of AAV2-NAB that lasted from day 8 to day 27 after readministration of AAV2/8 vector were 10-fold higher than its initial AAV2-NAB response following the first vector administration with AAV2 vector.
The AAV2-NAB response in C52, who received a low dose of AAV2 vector (2.8x10 11 GC/kg), was relatively weak and short lived. Six weeks after the injection,
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On day 1179, the dog was readministrated with a high dose of AAV2/5-cFIX vector (2.3x10 13 GC/kg). High titer of AAV5-NAB appeared 7 days after the readministration, and persisted during the following two years (Fig. 4C) . AAV2-NAB remained undetectable after readministration. As summarized in Table 1 , the three hemophilia B dogs, two naïve dogs (G43 and H12) and one AAV2-pretreated dog (D39), all demonstrated long-term expression of functional cFIX at the levels ranging from 10% to 26% of normal levels for over 1-2 years since intraportal infusion of the AAV2/8 vector. The vector doses ranged from 5.25x10 12 GC/kg to 9.28x10 12 GC/kg, equivalent to or 2-fold higher than the dose we used to treat a hemophilia B dog with AAV2 vector previously (4.6x10 12 GC/kg). 8 The highest expression came from G43, the only male dog among the three, even though it received a lower vector dose than D39. Whether the gender plays a role in influencing the transduction of canine liver by AAV2/8 remains to be investigated by increasing the sample numbers. Davidoff et al reported 5-to 13-folder higher gene expression in male mice by AAV2-or AAV5-mediated hepatic gene transfer and indicated the role played by androgens. 29 After readministration with AAV2/8 vector, the AAV2-pretreated dog D39 showed persistent expression of 16% of normal, suggesting that the pre-exposing to AAV2 does not prohibit AAV2/8 gene transfer, although at the time of readministration, the NAB to AAV2 was below the detection level. Figure 5 depicted the cFIX expression levels in the 5 hemophilia B dogs normalized to ng/ml/10 12 GC/kg. Compared to the dog Wilson, manuscript in preparation). C52, an AAV2-pretreated dog, has had a stable expression of 16% of normal level since the readministration of high dose of AAV2/5
vector. This level in C52 was close to the level in D39 who received a 2.5-fold less vector dose of AAV2/8. Normalized to ng/ml/10 12 GC/kg, the cFIX level in C52 was slightly lower than it was in C55, and 2.4-to 7.1-fold less than it was in AAV2/8-treated dogs (Fig.5 ). Based on data from these dogs, we conclude that AAV2/8 is about 1.5-4.3
fold more efficient than AAV2, and 2-7 fold more efficient than AAV2/5 for hepatic gene transfer in dogs.
In all four dogs, an early peak expression of cFIX was detected between day 4 to day 7 after vector administration ranging from 1.3 µg/ml (G43, d4-9), 3.8 µg/ml (H12, d5), 4.6 µg/ml (C52, d7) to 10.4 µg/ml (D39, d6). The normal canine plasma infusions before and after the surgery could contribute to some part of these cFIX peak expressions, however, the majorities are likely derived from the AAV vectors based on the calculation of the amount of plasma infused, the half life of cFIX, and the duration curve of FIX after IV administration. 30 Rapid uncoating has been recently proposed as a mechanism for efficient liver transduction in mouse liver by AAV8 vectors. 31 Similar mechanism may also apply to AAV8 or AAV5 transduction in canine liver, since C52 who received AAV2/5 vector also had the peak expression at day 7. The peak expression could be derived from the annealing of the complementary plus and minus ss genomes 32 , however, this form of DNA might not be very stable in majority of the hepatocytes, thus cause the rapid fall in FIX levels.
Early peak of transgene expression has also been observed in nonhuman primates following AAV-mediated hepatic gene transfer in our lab (J.Wilson and G.Gao, unpublished data).
In all four treated dogs, WBCT has been corrected close to normal ranges, especially in C52, a further reduction of WBCT was observed after the readministration with AAV2/5 vector. aPTT has also been reduced in all four dogs, and further reductions of aPTT have been observed in both D39 and C52 after the second injection.
Based on the results of the barium sulfate precipitation experiments, cFIX in the circulation generated by AAV vector treatment was less than fully gamma carboxylated.
It is possible that some hepatocytes are transduced with high copies of vector, which leads to over expression of FIX in excess of the capacity of the cell to fully accomplish the extensive post-transcriptional modifications essential for biogenesis of mature of FIX.
G43 had almost twice the antigen level than D39 assayed by ELISA, yet its average aPTT value was only slightly lower than D39. Nevertheless, none of the four dogs has had any spontaneous bleeding event since the injection of AAV2/8 or 2/5 vectors.
The reactivation of anti-AAV2 NAB in D39 following AAV2/8 vector delivery was unexpected. One possibility is that due to the high homology between the capsid protein of AAV2 and AAV8 (83% similarity), there might be some common epitopes between these two serotypes. Following readministration of AAV2/8 vector in D39, some AAV2-memory B cells might be reactivated by the input AAV8 capsids. Cross neutralization between AAV2 and AAV8 is also possible, as we have seen in sera from
For personal use only. on October 23, 2017 . by guest www.bloodjournal.org From rabbits immunized with AAV2 or AAV2/8 vectors, however, the equivalent high titers to AAV2 and AAV8 in D39 make this explanation less likely since usually the titers for the 'crossed' serotypes are significantly reduced (>16-fold). This observation should be further investigated in more dogs or other animal models. Reactivation of anti-AAV2 NAB was not observed in C52 following AAV2/5 vector administration. Compared to AAV8, AAV5 shares less sequence homology with AAV2 (56% identical) 33 and is more distantly related to AAV2 in phylogeny analysis 13 . Besides, cross neutralization between AAV2 and AAV5 was not detected in immunized rabbit sera 13 .
While these experiments were not formal toxicology studies using vector made under Good Manufacturing Practices, they do provide some information regarding 
